JP2004503243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004503243A5 JP2004503243A5 JP2002510682A JP2002510682A JP2004503243A5 JP 2004503243 A5 JP2004503243 A5 JP 2004503243A5 JP 2002510682 A JP2002510682 A JP 2002510682A JP 2002510682 A JP2002510682 A JP 2002510682A JP 2004503243 A5 JP2004503243 A5 JP 2004503243A5
- Authority
- JP
- Japan
- Prior art keywords
- binding agent
- cell
- vector
- nucleic acid
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011230 binding agent Substances 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 150000007523 nucleic acids Chemical group 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108010051696 Growth Hormone Proteins 0.000 description 7
- 102100038803 Somatotropin Human genes 0.000 description 7
- 239000000122 growth hormone Substances 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 102100020948 Growth hormone receptor Human genes 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108010068542 Somatotropin Receptors Proteins 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 102100028892 Cardiotrophin-1 Human genes 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 108090000630 Oncostatin M Proteins 0.000 description 2
- 102000004140 Oncostatin M Human genes 0.000 description 2
- 108010041776 cardiotrophin 1 Proteins 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- -1 IL- 7 Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0014765A GB0014765D0 (en) | 2000-06-16 | 2000-06-16 | Binding agent |
| GB0105969A GB0105969D0 (en) | 2001-03-10 | 2001-03-10 | Binding agent |
| GB0106487A GB0106487D0 (en) | 2001-03-16 | 2001-03-16 | Agent |
| PCT/GB2001/002645 WO2001096565A2 (en) | 2000-06-16 | 2001-06-18 | Binding agents: chimeric ligand/receptor proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004503243A JP2004503243A (ja) | 2004-02-05 |
| JP2004503243A5 true JP2004503243A5 (https=) | 2007-11-15 |
| JP4660062B2 JP4660062B2 (ja) | 2011-03-30 |
Family
ID=27255767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002510682A Expired - Fee Related JP4660062B2 (ja) | 2000-06-16 | 2001-06-18 | 結合剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7446183B2 (https=) |
| EP (2) | EP2316944A3 (https=) |
| JP (1) | JP4660062B2 (https=) |
| AU (1) | AU2001274234A1 (https=) |
| CA (1) | CA2447632C (https=) |
| WO (1) | WO2001096565A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4660062B2 (ja) * | 2000-06-16 | 2011-03-30 | アステリオン・リミテッド | 結合剤 |
| GB2389115B (en) * | 2001-12-14 | 2005-03-16 | Asterion Ltd | Polypeptide having a plurality of modified growth hormone receptor binding domains of growth hormone |
| JP2007527695A (ja) | 2003-04-09 | 2007-10-04 | アステリオン・リミテッド | グリコシルホスファチジルイノシトールを含有するポリペプチド |
| DE10353593A1 (de) * | 2003-11-17 | 2005-06-23 | Klinikum der Universität München Großhadern-Innenstadt | Leptinantagonist und Verfahren zur quantitativen Messung von Leptin |
| EP1771467A2 (en) * | 2004-07-26 | 2007-04-11 | Asterion Limited | Linkers |
| GB0600122D0 (en) * | 2006-01-05 | 2006-02-15 | Univ Cardiff | Mutation in the growth hormone receptor |
| GB0606946D0 (en) * | 2006-04-06 | 2006-05-17 | Asterion Ltd | Polypeptide antagonist |
| GB0618082D0 (en) * | 2006-09-14 | 2006-10-25 | Asterion Ltd | Growth factor |
| GB0717985D0 (en) | 2007-07-20 | 2007-10-24 | Asterion Ltd | Growth hormone fusion proteins |
| EP2185582A2 (en) * | 2007-08-03 | 2010-05-19 | Asterion Limited | Erythropoietin fusion proteins |
| US20110182848A1 (en) * | 2007-08-03 | 2011-07-28 | Asterion Limited | Granulocyte colony stimulating factor |
| GB0715216D0 (en) * | 2007-08-03 | 2007-09-12 | Asterion Ltd | Leptin |
| GB0715213D0 (en) * | 2007-08-06 | 2007-09-12 | Asterlon Ltd | Igf-1 |
| GB0715383D0 (en) * | 2007-08-08 | 2007-09-19 | Asterion Ltd | Interferon |
| GB0719818D0 (en) * | 2007-10-11 | 2007-11-21 | Asterion Ltd | Growth hormone fusion polypeptides |
| WO2009077731A2 (en) * | 2007-12-19 | 2009-06-25 | Asterion Limited | Prolactin fusion proteins |
| GB0725201D0 (en) * | 2007-12-24 | 2008-01-30 | Asterion Ltd | Peptide fusion proteins |
| JP2011512134A (ja) * | 2008-02-19 | 2011-04-21 | アステリオン・リミテッド | 修飾リンカー |
| GB0808402D0 (en) * | 2008-05-09 | 2008-06-18 | Asterion Ltd | Tsh |
| GB0812019D0 (en) * | 2008-07-02 | 2008-08-06 | Asterion Ltd | Insulin |
| GB201104285D0 (en) * | 2011-03-15 | 2011-04-27 | Asterion Ltd | Modified receptor fusion proteins |
| EP2606908A1 (en) | 2011-12-19 | 2013-06-26 | Ipsen Pharma S.A.S. | Novel pharmaceutical composition for a long acting growth hormone fusion protein (LAGH) |
| RS61391B1 (sr) | 2012-06-08 | 2021-02-26 | Alkermes Pharma Ireland Ltd | Ligandi modifikovani primenom cirkularnog permutiranja kao agonisti i antagonisti |
| GB201520021D0 (en) * | 2015-11-13 | 2015-12-30 | Asterion Ltd | Fusion polypeptide |
| US20220396609A1 (en) * | 2019-11-01 | 2022-12-15 | Senti Biosciences, Inc. | Chimeric receptor sensors |
| IL306074A (en) | 2021-03-24 | 2023-11-01 | Alkermes Inc | UPAR antibodies and fusion proteins with them |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK151585D0 (da) | 1985-04-03 | 1985-04-03 | Nordisk Gentofte | Dna-sekvens |
| US4857637A (en) * | 1986-05-07 | 1989-08-15 | Genentech, Inc. | Methods and compositions for immunologically modulating growth hormone receptor activity |
| EP0441889A1 (fr) | 1988-11-07 | 1991-08-21 | Commission des Communautés Européennes | Hormone de croissance humaine modifiee |
| JP3417558B2 (ja) | 1991-05-10 | 2003-06-16 | ジェネンテク，インコーポレイテッド | 配位子作用薬および拮抗薬の選択 |
| DE741187T1 (de) * | 1995-05-05 | 1997-04-30 | Hoffmann La Roche | Rekombinante Obesitäts-(OB)-Proteine |
| CA2230492C (en) | 1995-09-21 | 2009-05-26 | Genentech, Inc. | Human growth hormone variants |
| DE19608813C2 (de) * | 1996-03-07 | 1998-07-02 | Angewandte Gentechnologie Syst | Konjugat zur Beeinflussung von Wechselwirkungen zwischen Proteinen |
| US6187564B1 (en) * | 1997-07-10 | 2001-02-13 | Beth Israel Deaconess Medical Center | DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics |
| IL122818A0 (en) | 1997-07-10 | 1998-08-16 | Yeda Res & Dev | Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof |
| JPH11285388A (ja) | 1998-04-03 | 1999-10-19 | Jcr Pharmaceuticals Co Ltd | キメラレセプター発現細胞とその用途 |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| JP4660062B2 (ja) * | 2000-06-16 | 2011-03-30 | アステリオン・リミテッド | 結合剤 |
| GB2389115B (en) * | 2001-12-14 | 2005-03-16 | Asterion Ltd | Polypeptide having a plurality of modified growth hormone receptor binding domains of growth hormone |
-
2001
- 2001-06-18 JP JP2002510682A patent/JP4660062B2/ja not_active Expired - Fee Related
- 2001-06-18 US US10/311,473 patent/US7446183B2/en not_active Expired - Fee Related
- 2001-06-18 AU AU2001274234A patent/AU2001274234A1/en not_active Abandoned
- 2001-06-18 WO PCT/GB2001/002645 patent/WO2001096565A2/en not_active Ceased
- 2001-06-18 EP EP10075428A patent/EP2316944A3/en not_active Withdrawn
- 2001-06-18 CA CA2447632A patent/CA2447632C/en not_active Expired - Fee Related
- 2001-06-18 EP EP01940731A patent/EP1290170A2/en not_active Withdrawn
-
2008
- 2008-07-18 US US12/175,582 patent/US8173782B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004503243A5 (https=) | ||
| CA2447632A1 (en) | Fusion protein agonist comprising a growth hormone binding portion and an external domain of a growth hormone receptor | |
| JP2010531134A5 (https=) | ||
| JP6853317B2 (ja) | 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン | |
| Hirano | Interleukin-6 and its relation to inflammation and disease | |
| Sutherland et al. | Interleukin 4 is at 5q31 and interleukin 6 is at 7p15 | |
| Sehgal et al. | Human β2 interferon and B-cell differentiation factor BSF-2 are identical | |
| Feghali et al. | Cytokines in acute and chronic inflammation | |
| Fitzgerald et al. | The cytokine factsbook and webfacts | |
| Le et al. | Biology of disease | |
| AU782496B2 (en) | Immunoglobulin fusion proteins | |
| Kishimoto | Interleukin-6 and its receptor in autoimmunity | |
| CN100488984C (zh) | 降低融合蛋白的免疫原性 | |
| US20090221477A1 (en) | Linkers | |
| RU2009141975A (ru) | Слитные белки иммуноглобулинов | |
| CA2178482A1 (en) | Thrombopoietin | |
| CA2429384A1 (en) | Concatameric immunoadhesion | |
| JP2006519170A5 (https=) | ||
| JP2009096810A (ja) | 成長ホルモンおよび関連タンパク質の誘導体 | |
| TROTTA | Cytokines: an overview | |
| JP4747238B2 (ja) | 生物応答修飾タンパク質の効力を改善する方法及び典型的な突然変異タンパク質 | |
| RU2004121969A (ru) | Мультимеры рецептор-связывающих лигандов | |
| Opdenakker et al. | Interaction of interferon with other cytokines | |
| Pletnev et al. | A model of the ternary complex of interleukin-10 with its soluble receptors | |
| ZAV'YALOV et al. | Interferons α/β and their receptors: place in the hierarchy of cytokines |